The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives

Keys. ADC = antibody drug conjugate; ChT = cytotoxic chemotherapy; HER1-4 = human epidermal growth factor receptor 1-4; mUC = metastatic urothelial cancer; MoAb = monoclonal antibody; P = phosphate group; PD-L1 = programmed death ligand-1; TDM-1 = trastuzumab-emtansine; T-DXd = trastuzumab-deruxtecan; TKI = tyrosine kinase inhibitor.Created with BioRender.com. Color should be used for this figure in print.In this systematic review, 33 clinical trials were selected with respect to HER2-targeting in metastatic urothelial cancer (mUC).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research